Trial · NCT04960202
Results by group234
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 234
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Covid-19 Related Hospitalization or Death From Any Cause Through Day 28- Modified Intent-To-Treat (mITT) Population | PF-07321332 300 mg + Ritonavir 100 mg | 0.752 | 95% Confidence Interval 0.313 to 1.796 | Percentage of participants | |
| Percentage of Participants With Covid-19 Related Hospitalization or Death From Any Cause Through Day 28- Modified Intent-To-Treat (mITT) Population | Placebo | 6.888 | 95% Confidence Interval 5.172 to 9.146 | Percentage of participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | PF-07321332 300 mg + Ritonavir 100 mg | 228 | Participants | ||
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Placebo | 256 | Participants | ||
| Number of Participants With AEs Leading to Discontinuation and Serious Adverse Events (SAEs) | PF-07321332 300 mg + Ritonavir 100 mg | AEs leading to study discontinuation | 0 | Participants | |
| Number of Participants With AEs Leading to Discontinuation and Serious Adverse Events (SAEs) | Placebo | AEs leading to study discontinuation | 13 | Participants | |
| Number of Participants With AEs Leading to Discontinuation and Serious Adverse Events (SAEs) | PF-07321332 300 mg + Ritonavir 100 mg | SAEs | 18 | Participants | |
| Number of Participants With AEs Leading to Discontinuation and Serious Adverse Events (SAEs) | Placebo | SAEs | 71 | Participants | |
| Percentage of Participants With Covid-19 Related Hospitalization or Death From Any Cause Through Day 28- Modified Intent-To-Treat 1 (mITT1) Population | PF-07321332 300 mg + Ritonavir 100 mg | 0.933 | 95% Confidence Interval 0.487 to 1.786 | Percentage of participants | |
| Percentage of Participants With Covid-19 Related Hospitalization or Death From Any Cause Through Day 28- Modified Intent-To-Treat 1 (mITT1) Population | Placebo | 6.571 | 95% Confidence Interval 5.180 to 8.318 | Percentage of participants | |
| Time to Sustained Alleviation of All Targeted COVID-19 Signs and Symptoms Through Day 28- mITT Population | PF-07321332 300 mg + Ritonavir 100 mg | 12.00 | 95% Confidence Interval 12.00 to 13.00 | Days | |
| Time to Sustained Alleviation of All Targeted COVID-19 Signs and Symptoms Through Day 28- mITT Population | Placebo | 15.00 | 95% Confidence Interval 13.00 to 16.00 | Days | |
| Time to Sustained Alleviation of All Targeted COVID-19 Signs and Symptoms Through Day 28- mITT1 Population | PF-07321332 300 mg + Ritonavir 100 mg | 13.00 | 95% Confidence Interval 12.00 to 13.00 | Days | |
| Time to Sustained Alleviation of All Targeted COVID-19 Signs and Symptoms Through Day 28- mITT1 Population | Placebo | 15.00 | 95% Confidence Interval 14.00 to 16.00 | Days | |
| Time to Sustained Alleviation of All Targeted COVID-19 Signs and Symptoms Through Day 28- Modified Intent-to-Treat 2 (mITT2) Population | PF-07321332 300 mg + Ritonavir 100 mg | 13.00 | 95% Confidence Interval 12.00 to 13.00 | Days | |
| Time to Sustained Alleviation of All Targeted COVID-19 Signs and Symptoms Through Day 28- Modified Intent-to-Treat 2 (mITT2) Population | Placebo | 16.00 | 95% Confidence Interval 15.00 to 17.00 | Days | |
| Percentage of Participants With Severe Covid-19 Signs and Symptoms Through Day 28- mITT Population | PF-07321332 300 mg + Ritonavir 100 mg | 18.168 | Percentage of participants | ||
| Percentage of Participants With Severe Covid-19 Signs and Symptoms Through Day 28- mITT Population | Placebo | 20.775 | Percentage of participants | ||
| Percentage of Participants With Severe Covid-19 Signs and Symptoms Through Day 28- mITT1 Population | PF-07321332 300 mg + Ritonavir 100 mg | 19.691 | Percentage of participants | ||
| Percentage of Participants With Severe Covid-19 Signs and Symptoms Through Day 28- mITT1 Population | Placebo | 21.298 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04960202/results